

FAX

Tender Results

To: All Suppliers and Wholesalers

From: Yvonne Chen

Date: 27 February 2009

No of Pages (including this one): 2

Dear Supplier/Wholesaler

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products listed in the Invitation to Tender dated 15 December 2006 and the Invitation to Tender dated 21 December 2007.

Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly.

Product Notification Forms

Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) suppliers are required to notify PHARMAC and the Guild by 4pm **12th March 2009**. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp.

2006/07 Tender

1. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on **1 April 2009**, reference pricing of non-tender winning brand will occur on **1 June 2009** and Sole Subsidised Supply commences on **1 September 2009**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	New tender subsidy	Current subsidy	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Ropinirole hydrochloride*	Tab 0.25 mg; 84 tablets, bottle	\$7.90 (84 tablets)	\$31.50 (210 tablets)	Ropin (Pacific)	Requip (GSK)
Ropinirole hydrochloride*	Tab 1 mg; 84 tablets, bottle	\$40.32	\$67.20	Ropin (Pacific)	Requip (GSK)
Ropinirole hydrochloride*	Tab 2 mg; 84 tablets, bottle	\$60.72	\$101.21	Ropin (Pacific)	Requip (GSK)
Ropinirole hydrochloride*	Tab 5 mg; 84 tablets, bottle	\$90.00	\$150.00	Ropin (Pacific)	Requip (GSK)

* Reference pricing will also occur on 1 June 2009 for the Requip Starter Pack (\$21.92) and the Requip Follow-on pack (\$73.60). Requip Starter Pack and Requip Follow-on Pack will also be delisted from 1 September 2009.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – listing for hospital tender winning brands of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 April 2009**; DV Limits and DV pharmaceuticals will apply from **1 June 2009**; De-listing of other brands in Section H will occur on **1 June 2009**.

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Gemcitabine hydrochloride	Inj 200 mg; 1 injection, vial	Gemcitabine Ebewe (InterPharma)	\$49.00	1%	Gemzar (Eli Lilly)
Gemcitabine hydrochloride	Inj 1 g; 1 injection, vial	Gemcitabine Ebewe (InterPharma)	\$245.00	1%	Gemzar (Eli Lilly)
Ropinirole hydrochloride*	Tab 0.25 mg; 84 tablets, bottle	Ropin (Pacific)	\$7.90	1%	Requip (GSK)
Ropinirole hydrochloride*	Tab 1 mg; 84 tablets, bottle	Ropin (Pacific)	\$40.32	1%	Requip (GSK)
Ropinirole hydrochloride*	Tab 2 mg; 84 tablets, bottle	Ropin (Pacific)	\$60.72	1%	Requip (GSK)
Ropinirole hydrochloride*	Tab 5 mg; 84 tablets, bottle	Ropin (Pacific)	\$90.00	1%	Requip (GSK)

*Requip Starter Pack and Requip Follow-on Pack will also be delisted from Section H on 1 June 2009.

2007/08 Tender

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 21 December 2007.

The decisions were as follows:

Chemical Name	Line Item
Mirtazapine	Tab 15 mg
Mirtazapine	Tab 30 mg
Mirtazapine	Tab 45 mg
Orphenadrine Citrate	Tab 100 mg
Sodium Citrate with Sodium Lauryl Sulphoacetate	Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml
Sodium Fluorescein	Inj 1 g per 10 ml

For the remaining products on the Invitation to Tender dated 21 December 2007 and the Invitation to tender dated 15 December 2006 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock. We will keep you informed regarding any changes for the remaining tender products as further decisions are made.

Yours sincerely



Yvonne Chen
Tender Analyst